News - Cardio-vascular, Merck & Co

Filter

Current filters:

Cardio-vascularMerck & Co

Popular Filters

1 to 25 of 40 results

High potency statins linked to better outcome following a heart attack

21-02-2014

A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment…

Cardio-vascularezetimibeMerck & CoPharmaceuticalResearchZetia

FDA advisory panel votes to approve Merck & Co’s vorapaxar

FDA advisory panel votes to approve Merck & Co’s vorapaxar

16-01-2014

There was a positive outcome for US pharma giant Merck & Co yesterday, when a US Food and Drug Administration…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationUSAvorapaxarZontivity

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

14-01-2014

US drug giant Merck & Co says it has started a rolling submission to the US Food and Drug Administration…

Cardio-vascularMerck & CoMK-3475North AmericaOncologyPharmaceuticalRegulationUSAvorapaxarZontivity

New ACC and AHA guidelines could increase sales of statins

New ACC and AHA guidelines could increase sales of statins

13-11-2013

New clinical guidelines have been published for the treatment of cholesterol in people at high risk of…

AbbVieAstraZenecaCardio-vascularCrestorHealthcareLipitorMerck & CoNorth AmericaPfizerPharmaceuticalTricorUSAZetia

Akrikhin expands deal with Merck & Co

08-08-2013

Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck &…

Akrikhin PharmaceuticalsCardio-vascularDiabetesEuropeEzetrolJanumetJanuviaMarkets & MarketingMerck & CoNoxafilPharmaceuticalProductionRespiratory and PulmonarySingulair

Merck & Co's NDA for vorapaxar accepted for standard review by US FDA

25-07-2013

US pharma giant Merck & Co (NYSE: MRK) has said the New Drug Application (NDA) for its once-troubled…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationvorapaxar

Cardiome signs deal with AOP Orphan to market CAF drug Brinavess

04-07-2013

Canada-based Cardiome Pharma (TSX: COM) has signed an agreement with Austrian firm AOP Orphan Pharmaceuticals…

AOP OrphanBrinavessCardio-vascularCardiome PharmaMerck & CoPharmaceutical

Cardiome gains European MA rights for Brinavess from Merck & Co

27-06-2013

Canada-based Cardiome Pharma (TSX: COM) has announced adoption of the decision by the European Commission…

BrinavessCardio-vascularCardiome PharmaEuropeLicensingMerck & CoPharmaceuticalRegulation

US FDA approves Merck & Co's combo cholesterol drug Liptruzet

06-05-2013

The Food and Drug Administration has approved pharma giant Merck & Co's (NYSE: MRK) Liptruzet (ezetimibe…

atorvastatinCardio-vascularezetimibeLiptruzetMerck & CoNorth AmericaPharmaceuticalRegulation

Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon

23-04-2013

US pharma giant Merck & Co (NYSE: MRK) has entered into a non-exclusive agreement with drug major Bristol-Myers…

Anti-viralsBristol-Myers SquibbCardio-vasculardaclatasvirLicensingMerck & CoMK-5172PharmaceuticalResearchXenon Pharmaceuticals

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Merck & Co gets all clear to continue Vytorin study; FDA warns on Pfizer's Zithromax

13-03-2013

US pharma giant Merck & Co said yesterday that the Data Safety Monitoring Board (DSMB) of the IMPROVE-IT…

Antibiotics and Infectious diseasesCardio-vascularMerck & CoNorth AmericaPfizerPharmaceuticalRegulationResearchVytorinZithromax

Niacin causes serious unexpected side-effects, but no worthwhile benefits, for at risk patients

11-03-2013

Adding extended-release (ER) niacin to statins does not reduce the chances of high risk patients having…

Cardio-vascularMerck & ConiacinPharmaceuticalResearchTredaptive

EMA Pharmacovigilance committee calls for Tredaptive suspension; contraceptives update

13-01-2013

At meetings held last week, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee…

Cardio-vascularEuropeMerck & CoNeurologicalPharmaceuticalRegulationReproductivetetrazepamTredaptive

EMA starts review of Merck & Co's cholesterol drug Tredaptive

24-12-2012

The European Medicines Agency said on December 21 that it has started a review of the safety and efficacy…

anacetrapibCardio-vascularEli LillyEuropeevacetrapibMerck & CoPharmaceuticalRegulationTredaptive

Merck & Co to drop Tredaptive development in USA

21-12-2012

US drug giant Merck & Co (NYSE: MRK) said yesterday that, following disappointing clinical trial results…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationResearchTredaptive

Germany invalidates Seroquel patent; Merck drops combo diabetes drug development

14-11-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said last evening that the Federal Patent Court in Germany…

AstraZenecaatorvastatinCardio-vascularDiabetesJanuviaMerck & CoMK-0431ENeurologicalPatentsPharmaceuticalResearchSeroquel XR

Theravance and Merck & Co enter cardiovascular disease accord

17-10-2012

Drug developer Theravance (Nasdaq: THRX) has signed a collaboration agreement with pharma giant Merck…

Cardio-vascularLicensingMerck & CoPharmaceuticalTheravance

Merck & Co returns vernakalant rights to Cardiome

27-09-2012

Canada-based Cardiome Pharma (Nasdaq: CRME) saw its shares go into free-fall, dropping 54.4% to close…

BrinavessCardio-vascularCardiome PharmaLicensingMerck & CoPharmaceuticalvernakalant

Merck & Co to file for approval of two heart drugs next year

28-08-2012

US drugs giant Merck & Co (NYSE: MRK) says that, following a review of the clinical trial data and discussions…

anacetrapibCardio-vascularEuropeMerck & CoNorth AmericaPharmaceuticalRegulationResearchTredaptivevorapaxar

1 to 25 of 40 results

Back to top